Bin Tean Teh

List of Publications by Year
in descending order

292 papers	28,679 citations	4370 86 h-index	6113 159 g-index
306 all docs	306 docs citations	306 times ranked	35895 citing authors

#	Article	IF	Citations
1	NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	6
2	Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers. Cancers, 2022, 14, 576.	1.7	6
3	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. Cell Reports Medicine, 2022, 3, 100526.	3.3	7
4	Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. Npj Breast Cancer, 2022, 8, 44.	2.3	4
5	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. American Journal of Hematology, 2022, 97, 1159-1169.	2.0	4
6	Paediatric <scp>BCOR</scp>â€associated sarcomas with a novel long spliced internal tandem duplication of <scp>BCOR</scp> exon 15. Journal of Pathology: Clinical Research, 2022, 8, 470-480.	1.3	1
7	Targeting the IRAK1â€“S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research, 2021, 81, 1413-1425.	0.4	19
8	Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Medicine, 2021, 13, 3.	3.6	19
9	Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing. Modern Pathology, 2021, 34, 1320-1332.	2.9	19
10	Cholangiocarcinoma. Nature Reviews Disease Primers, 2021, 7, 65.	18.1	270
11	CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Letters, 2021, 521, 268-280.	3.2	10
12	Involvement of PBRM1 in VHL diseaseâ€‘associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. Oncology Letters, 2021, 22, 835.	0.8	5
13	Genetic and Epigenetic Alterations in Cancer. , 2020, , 209-224.e2.		5
14	Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut, 2020, 69, 1039-1052.	6.1	36
15	MED12, TERT and RARA in fibroepithelial tumours of the breast. Journal of Clinical Pathology, 2020, 73, 51-56.	1.0	25
16	Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma. Liver Cancer International, 2020, 1, 25-35.	0.2	5
17	Functional characterisation guides classification of novel BAP1 germline variants. Npj Genomic Medicine, 2020, 5, 50.	1.7	3
18	Morphologic and genetic heterogeneity in breast fibroepithelial lesionsâ€”a comprehensive mapping study. Modern Pathology, 2020, 33, 1732-1745.	2.9	13

#	Article	IF	Citations
19	Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Human Cell, 2020, 33, 695-708.	1.2	69
20	An Optimised Protocol Harnessing Laser Capture Microdissection for Transcriptomic AnalysisÂon Matched Primary and Metastatic Colorectal Tumours. Scientific Reports, 2020, 10, 682.	1.6	11
21	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	0.8	35
22	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	3.9	12
23	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. Journal of Clinical Investigation, 2020, 130, 5833-5846.	3.9	58
24	Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable inherited disorders. Genetics in Medicine, 2019, 21, 207-212.	1.1	18
25	Genomic characterisation of breast fibroepithelial lesions in an international cohort. Journal of Pathology, 2019, 249, 447-460.	2.1	33
26	The utility of a targeted gene mutation panel in refining the diagnosis of breast phyllodes tumours. Pathology, 2019, 51, 531-534.	0.3	7
27	Digital phenotyping by consumer wearables identifies sleep-associated markers of cardiovascular disease risk and biological aging. Communications Biology, 2019, 2, 361.	2.0	34
28	A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Medical Genomics, 2019, 12, 142.	0.7	20
29	Implementation of genomics in medical practice to deliver precision medicine for an Asian population. Npj Genomic Medicine, 2019, 4, 12.	1.7	17
30	The importance of including diverse populations in cancer genomic and epigenomic studies. Nature Reviews Cancer, 2019, 19, 361-362.	12.8	6
31	Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell, 2019, 35, 932-947.e8.	7.7	182
32	Assessment of different strategies for scalable production and proliferation of human myoblasts. Cell Proliferation, 2019, 52, e12602.	2.4	11
33	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. Journal of Dental Research, 2019, 98, 652-658.	2.5	14
34	Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma. Scientific Reports, 2019, 9, 2552.	1.6	15
35	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676.	0.6	184
36	Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. Journal of Cancer, 2019, 10, 5130-5138.	1.2	1

#	Article	IF	Citations
37	Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours. Breast Cancer Research and Treatment, 2019, 174, 365-373.	1.1	20
38	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epsteinâ€“Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	0.8	1
39	In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Research, 2018, 28, 654-665.	2.4	126
40	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	7.7	175
41	Genetics and genomics of breast fibroadenomas. Journal of Clinical Pathology, 2018, 71, 381-387.	1.0	27
42	Molecular insights into paediatric breast fibroepithelial tumours. Histopathology, 2018, 73, 809-818.	1.6	11
43	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	6.0	134
44	Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Research, 2018, 20, 22.	2.2	15
45	Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. International Journal of Oncology, 2018, 53, 1455-1468.	1.4	9
46	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	0.6	70
47	Transcriptional analysis of immune genes in Epsteinâ€“Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21, 1064-1070.	2.7	25
48	Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. PLoS Biology, 2018, 16, e2004285.	2.6	57
49	Genomics of worms, with an emphasis on Opisthorchis viverrini â€" opportunities for fundamental discovery and biomedical outcomes. Parasitology International, 2017, 66, 341-345.	0.6	7
50	Molecular Genetics of Renal Cell Carcinoma. , 2017, , 83-103.		1
51	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	0.9	34
52	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	5.8	165
53	Osteoblast-specific deletion of Hrpt2/Cdc73 results in high bone mass and increased bone turnover. Bone, 2017, 98, 68-78.	1.4	10
54	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48

#	Article	IF	Citations
55	The draft genome of tropical fruit durian (Durio zibethinus). Nature Genetics, 2017, 49, 1633-1641.	9.4	150
56	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Science Translational Medicine, 2017, 9, .	5.8	272
57	A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology, 2017, 49, 786-789.	0.3	13
58	Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas. Scientific Reports, 2017, 7, 10660.	1.6	52
59	VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	7.7	111
60	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Scientific Reports, 2017, 7, 7342.	1.6	46
61	Misregulation of Histone Methylation Regulators in Cancer. Cancer Drug Discovery and Development, 2017, , 221-248.	0.2	2
62	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research, 2017, 27, 1475-1486.	2.4	90
63	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
64	Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nature Communications, 2017, 8, 15866.	5.8	42
65	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	7.7	637
66	Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight, 2017, 2, e92061.	2.3	84
67	Tiefe molekulare Characterisierung des Cholangiokarzinoms. , 2017, 55, .		0
68	Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. American Journal of Cancer Research, 2017, 7, 484-502.	1.4	1
69	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology, 2016, 151, 637-650.e10.	0.6	127
70	Germline hemizygous deletion of CDKN2Aâ€“CDKN2B locus in a patient presenting with Liâ€“Fraumeni syndrome. Npj Genomic Medicine, 2016, 1, 16015.	1.7	9
71	MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression. Journal of Clinical Pathology, 2016, 69, 858-865.	1.0	26
72	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports, 2016, 6, 19552.	1.6	26

#	Article	IF	Citations
73	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8, 195-202.	2.7	94
74	Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nature Medicine, 2016, 22, 666-671.	15.2	169
75	Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine, 2016, 22, 464-471.	15.2	83
76	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	3.8	8
77	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology, The, 2016, 17, 1240-1247.	5.1	84
78	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nature Communications, 2016, 7, 12983.	5.8	123
79	Defining the Molecular Alterations of Ampullary Carcinoma. Cancer Cell, 2016, 29, 135-136.	7.7	7
80	SETD2histone modifier loss in aggressive GI stromal tumours. Gut, 2016, 65, 1960-1972.	6.1	49
81	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	3.9	49
82	Generation of Non-Hodgkin Lymphoma Patient-Derived Xenografts and in Depth Characterization of a Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Model. Blood, 2016, 128, 4128-4128.	0.6	1
83	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Scientific Reports, 2015, 5, 13321.	1.6	113
84	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 2015, 7, 98.	3.6	74
85	Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Current Opinion in Gastroenterology, 2015, 31, 258-263.	1.0	45
86	MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. Journal of Clinical Pathology, 2015, 68, 685-691.	1.0	62
87	Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas. European Urology, 2015, 68, 77-83.	0.9	56
88	Whole-Exome Sequencing Studies of Parathyroid Carcinomas Reveal NovelPRUNE2Mutations, Distinctive Mutational Spectra Related to APOBEC-Catalyzed DNA Mutagenesis and Mutational Enrichment in Kinases Associated With Cell Migration and Invasion. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E360-E364.	1.8	86
89	Glypican 3 overexpression in primary and metastatic Wilms tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 67-76.	1.4	20
90	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 233-244.	1.0	34

#	Article	IF	Citations
91	An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases. Oral Oncology, 2015, 51, 355-362.	0.8	64
92	CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. Journal of Clinical Pathology, 2015, 68, 200-205.	1.0	32
93	Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney International, 2015, 88, 1057-1069.	2.6	27
94	Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma. Cancer Investigation, 2015, 33, 378-386.	0.6	11
95	A germline mutation inPBRM1predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	1.5	38
96	High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biology, 2015, 16, 32.	3.8	42
97	Genomic landscapes of breast fibroepithelial tumors. Nature Genetics, 2015, 47, 1341-1345.	9.4	167
98	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer Discovery, 2015, 5, 1133-1136.	7.7	45
99	Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Medicine, 2015, 7, 38.	3.6	87
100	Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. Oncotarget, 2015, 6, 32761-32773.	0.8	13
101	â€œSeed and Soilâ€•Theory of Metastasis. , 2015, , 1-2.		0
102	Inhibition of placental growth factor in renal cell carcinoma. Anticancer Research, 2015, 35, 531-41.	0.5	8
103	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. Anticancer Research, 2015, 35, 6639-53.	0.5	14
104	Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis. PLoS ONE, 2014, 9, e104158.	1.1	94
105	Chronic Kidney Disease and Upper Tract Urothelial Carcinomas. BioMed Research International, 2014, 2014, 1-2.	0.9	3
106	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	2.8	318
107	The Succinated Proteome of FH-Mutant Tumours. Metabolites, 2014, 4, 640-654.	1.3	48
108	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes. Clinical Cancer Research, 2014, 20, 4129-4140.	3.2	117

#	Article	IF	Citations
109	The Opisthorchis viverrini genome provides insights into life in the bile duct. Nature Communications, 2014, 5, 4378.	5.8	144
110	Upper Tract Urothelial Carcinomas in Patients with Chronic Kidney Disease: Relationship with Diagnostic Challenge. BioMed Research International, 2014, 2014, 1-9.	0.9	10
111	Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Medicine, 2014, 6, 24.	3.6	75
112	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nature Genetics, 2014, 46, 877-880.	9.4	172
113	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nature Communications, 2014, 5, 4361.	5.8	72
114	Abscisic acid perception and signaling: structural mechanisms and applications. Acta Pharmacologica Sinica, 2014, 35, 567-584.	2.8	174
115	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 2014, 123, 2915-2923.	0.6	435
116	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer, 2013, 119, 313-324.	2.0	43
117	Molecular targets on the horizon for kidney and urothelial cancer. Nature Reviews Clinical Oncology, 2013, 10, 557-570.	12.5	21
118	Exome sequencing identifies distinct mutational patterns in liver flukeâ€“related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	9.4	426
119	Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool. Science Translational Medicine, 2013, 5, 197ra101.	5.8	233
120	Gene profiling suggests a common evolution of bladder cancer subtypes. BMC Medical Genomics, 2013, 6, 42.	0.7	9
121	Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology, 2013, 145, 554-565.	0.6	381
122	Integrated epigenomics identifiesBMP4as a modulator of cisplatin sensitivity in gastric cancer. Gut, 2013, 62, 22-33.	6.1	88
123	Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells. Molecular Cancer Therapeutics, 2013, 12, 2157-2166.	1.9	43
124	The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 1717-1728.	3.2	83
125	Human Folliculin Delays Cell Cycle Progression through Late S and G2/M-Phases: Effect of Phosphorylation and Tumor Associated Mutations. PLoS ONE, 2013, 8, e66775.	1.1	15
126	Molecular Biology and Genetics. , 2013, , 19-37.		0

#	Article	IF	Citations
127	Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma. Cancer Research, 2012, 72, 4361-4371.	0.4	52
128	Janus Kinase 3â€“Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discovery, 2012, 2, 591-597.	7.7	236
129	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelialâ€“mesenchymal transition and activation of AKT signaling. Carcinogenesis, 2012, 33, 1302-1309.	1.3	118
130	Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Human Molecular Genetics, 2012, 21, 5268-5279.	1.4	50
131	Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. OncoImmunology, 2012, 1, 18-27.	2.1	53
132	Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factorâ€“mediated upregulation of caveolin-1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4892-4897.	3.3	120
133	The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. International Journal of Oncology, 2012, 41, 2139-2149.	1.4	26
134	Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer. Science Translational Medicine, 2012, 4, 156ra140.	5.8	163
135	Functional Importance of Dicer Protein in the Adaptive Cellular Response to Hypoxia. Journal of Biological Chemistry, 2012, 287, 29003-29020.	1.6	126
136	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genetics, 2012, 44, 570-574.	9.4	560
137	Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e482-e491.	5.1	30
138	Exome sequencing of liver flukeâ€“associated cholangiocarcinoma. Nature Genetics, 2012, 44, 690-693.	9.4	412
139	Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biology, 2012, 13, R115.	13.9	116
140	Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Canadian Urological Association Journal, 2012, 1, S21-7.	0.3	15
141	Renal Cell Carcinoma Deep Sequencing: Recent Developments. Current Oncology Reports, 2012, 14, 240-248.	1.8	11
142	Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Research and Treatment, 2012, 132, 143-151.	1.1	28
143	Molecular Characterization of Renal Cell Carcinoma. , 2012, , 91-111.		2
144	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2012, 30, 368-368.	0.8	1

#	Article	IF	Citations
145	Deregulation of E2-EPF Ubiquitin Carrier Protein in Papillary Renal Cell Carcinoma. American Journal of Pathology, 2011, 178, 853-860.	1.9	35
146	First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biology, 2011, 12, R96.	13.9	19
147	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	13.7	466
148	Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature, 2011, 469, 539-542.	13.7	1,127
149	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma. Cancer Cell, 2011, 20, 511-523.	7.7	347
150	Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Research and Treatment, 2011, 129, 319-329.	1.1	45
151	Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase Targets. Cancer Research, 2011, 71, 5225-5234.	0.4	31
152	Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis. Cancer Research, 2011, 71, 3162-3172.	0.4	133
153	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. Journal of Clinical Oncology, 2011, 29, e591-e594.	0.8	15
154	Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing. Cancer Research, 2011, 71, 29-39.	0.4	74
155	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1439-1444.	3.3	87
156	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Journal of Medical Genetics, 2011, 48, 226-234.	1.5	116
157	Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Modern Pathology, 2011, 24, 688-697.	2.9	59
158	FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomarker Insights, 2011, 6, BMI.S6487.	1.0	19
159	â€œSeed and Soilâ€•Theory of Metastasis. , 2011, , 3354-3355.		1
160	Assessing Matched Normal and Tumor Pairs in Next-Generation Sequencing Studies. PLoS ONE, 2011, 6, e17810.	1.1	7
161	p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. International Journal of Cancer, 2010, 126, 2353-2361.	2.3	51
162	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseâ€inhibiting therapy. BJU International, 2010, 106, 62-65.	1.3	46

#	Article	IF	Citations
163	Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer, 2010, 10, 196.	1.1	86
164	The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. Molecular Carcinogenesis, 2010, 49, 215-223.	1.3	30
165	Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Medical Genomics, 2010, 3, 58.	0.7	50
166	Birt-Hogg-DubÃ© renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Medical Genomics, 2010, 3, 59.	0.7	68
167	Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature, 2010, 463, 360-363.	13.7	1,062
168	Signatures of mutation and selection in the cancer genome. Nature, 2010, 463, 893-898.	13.7	661
169	CDC73/HRPT2 CpG island hypermethylation and mutation of 5â€²-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	1.6	37
170	Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. Cancer Research, 2010, 70, 1053-1062.	0.4	203
171	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. Cancer Research, 2010, 70, 1063-1071.	0.4	394
172	Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Molecular Cancer Therapeutics, 2010, 9, 1525-1535.	1.9	160
173	Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. Urology, 2010, 75, 1365-1370.e3.	0.5	36
174	Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncology, The, 2010, 11, 571-578.	5.1	46
175	Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma. Journal of Urology, 2010, 184, 859-864.	0.2	118
176	Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. Journal of Medical Case Reports, 2010, 4, 36.	0.4	6
177	An Integrated Oncogenomic Approach: From Genes to Pathway Analyses. , 2010, , 31-50.		0
178	VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2010, 2, 296-308.	0.0	36
179	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	1.8	120
180	Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models. Cancer Research, 2009, 69, 8256-8264.	0.4	60

#	Article	IF	Citations
181	Prognostic Value of Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clinical Cancer Research, 2009, 15, 650-659.	3.2	59
182	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer, 2009, 115, 2247-2251.	2.0	24
183	Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer, 2009, 115, 2282-2289.	2.0	96
184	Radiosensitization by Inhibiting STAT1 in Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 288-295.	0.4	52
185	Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics, 2009, 41, 521-523.	9.4	734
186	Regulation of endocytosis via the oxygen-sensing pathway. Nature Medicine, 2009, 15, 319-324.	15.2	178
187	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. American Journal of Surgical Pathology, 2009, 33, 72-80.	2.1	84
188	MicroRNA profiling of human kidney cancer subtypes. International Journal of Oncology, 2009, 35, 109-14.	1.4	135
189	A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases Journal, 2009, 2, 7769.	0.4	6
190	Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery, 2008, 143, 630-640.	1.0	52
191	A comparison study reveals important features of agreement and disagreement between summarized DNA and RNA data obtained from renal cell carcinoma. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 657, 77-83.	0.9	3
192	Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Letters, 2008, 272, 260-267.	3.2	27
193	Over Expression of Insulin-Like Growth Factor Binding Protein 3 in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 179, 445-449.	0.2	29
194	Parafibromin, a Component of the Human PAF Complex, Regulates Growth Factors and Is Required for Embryonic Development and Survival in Adult Mice. Molecular and Cellular Biology, 2008, 28, 2930-2940.	1.1	97
195	Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response. PLoS Genetics, 2008, 4, e1000176.	1.5	58
196	Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo. Cancer Research, 2008, 68, 81-88.	0.4	194
197	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	2.1	156
198	Renal Translocation Carcinomas. American Journal of Surgical Pathology, 2008, 32, 656-670.	2.1	232

#	Article	IF	Citations
199	Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia. PLoS ONE, 2008, 3, e3581.	1.1	131
200	Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma. Cancer Research, 2007, 67, 3171-3176.	0.4	141
201	Prospects for Vasculature Reorganization in Sentinel Lymph Nodes. Cell Cycle, 2007, 6, 514-517.	1.3	23
202	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. Molecular and Cellular Biology, 2007, 27, 157-169.	1.1	230
203	Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications. Clinical Cancer Research, 2007, 13, 161-169.	3.2	81
204	Human Kidney Injury Molecule-1 (hKIM-1): A Useful Immunohistochemical Marker for Diagnosing Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma. American Journal of Surgical Pathology, 2007, 31, 371-381.	2.1	90
205	Renal papillary adenomaâ€"a putative precursor of papillary renal cell carcinoma. Human Pathology, 2007, 38, 239-246.	1.1	67
206	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. International Journal of Cancer, 2007, 121, 992-998.	2.3	7
207	Patterns of somatic mutation in human cancer genomes. Nature, 2007, 446, 153-158.	13.7	2,802
208	Classification of Renal Neoplasms Based on Molecular Signatures. Journal of Urology, 2006, 175, 2302-2306.	0.2	70
209	Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochemical and Biophysical Research Communications, 2006, 350, 17-24.	1.0	84
210	Expression of S-100 protein in renal cell neoplasms. Human Pathology, 2006, 37, 462-470.	1.1	53
211	Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. Journal of Medical Investigation, 2006, 53, 9-19.	0.2	21
212	Glypican 3: A Novel Marker in Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2006, 30, 1570-1575.	2.1	174
213	HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncology, 2006, 42, 735-739.	0.8	95
214	Gene Expression Profiling in Kidney Cancer: Combining Differential Expression and Chromosomal and Pathway Analyses. Clinical Genitourinary Cancer, 2006, 5, 227-231.	0.9	2
215	Preparing the â€œSoilâ€: The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells. Cancer Research, 2006, 66, 10365-10376.	0.4	262
216	Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. American Journal of Clinical Pathology, 2006, 126, 79-85.	0.4	20

#	Article	IF	Citations
217	Genome-wide screening using array-CGH does not reveal microdeletions/microduplications in children with Kabuki syndrome. European Journal of Human Genetics, 2005, 13, 260-263.	1.4	22
218	Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer. Cancer Research, 2005, 65, 7591-7595.	0.4	429
219	Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM). Clinical Cancer Research, 2005, 11, 7064s-7069s.	3.2	20
220	Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein. Journal of Biological Chemistry, 2005, 280, 28507-28518.	1.6	122
221	A Molecular Classification of Papillary Renal Cell Carcinoma. Cancer Research, 2005, 65, 5628-5637.	0.4	226
222	Cystic Renal Neoplasia Following Conditional Inactivation of Apc in Mouse Renal Tubular Epithelium. Journal of Biological Chemistry, 2005, 280, 3938-3945.	1.6	124
223	Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA - Journal of the American Medical Association, 2005, 294, 2465.	3.8	218
224	C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Human Pathology, 2005, 36, 262-268.	1.1	94
225	Gene expression profiling of renal cell carcinoma and clinical implications. Urology, 2005, 65, 231-237.	0.5	5
226	Overexpression of glutathione s-transferase alpha in clear cell renal cell carcinoma. American Journal of Clinical Pathology, 2005, 123, 421-9.	0.4	19
227	Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis. Clinical Cancer Research, 2004, 10, 2368-2378.	3.2	49
228	Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients. Clinical Cancer Research, 2004, 10, 8204-8213.	3.2	80
229	Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma. Clinical Cancer Research, 2004, 10, 6629-6637.	3.2	223
230	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.4	96
231	A meiotic recombination in a new isolated familial somatotropinoma kindred. European Journal of Endocrinology, 2004, 150, 643-648.	1.9	38
232	Innovations and Challenges in Renal Cancer. Clinical Cancer Research, 2004, 10, 6277S-6281S.	3.2	38
233	Gene Expression Profiling of Renal Cell Carcinoma: Fig. 1.. Clinical Cancer Research, 2004, 10, 6315S-6321S.	3.2	39
234	Gene expression profiling of renal medullary carcinoma. Cancer, 2004, 100, 976-985.	2.0	101

#	Article	IF	Citations
235	Robust Classification of Renal Cell Carcinoma Based on Gene Expression Data and Predicted Cytogenetic Profiles. Cancer Research, 2004, 64, 4117-4121.	0.4	99
236	Gene expression profiling of mesoblastic nephroma and Wilms tumorsâ€"comparison and clinical implications. Urology, 2004, 64, 362-368.	0.5	15
237	Characterization of a new SNP c767A/T (Arg222Trp) in the candidate TSG FUS2 on human chromosome 3p21.3: prevalence in Asian populations and analysis of association with nasopharyngeal cancer. Molecular and Cellular Probes, 2004, 18, 39-44.	0.9	5
238	HRPT2 and parathyroid cancer. Lancet Oncology, The, 2004, 5, 78.	5.1	0
239	Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2004, 28, 1045-1050.	2.1	46
240	Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2004, 28, 69-76.	2.1	168
241	S13-3 Molecular sub-classification of renal cancer and new diagnostic markers. Japanese Journal of Urology, 2004, 95, 226.	0.0	0
242	The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell, 2003, 4, 405-413.	7.7	102
243	Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene, 2003, 22, 6810-6818.	2.6	192
244	Effect of Sildenafil Citrate on an Orthotopic Prostate Cancer Growth and Metastasis Model. Journal of Urology, 2003, 170, 994-997.	0.2	24
245	Gene expression profiling of endocrine tumors by microarray analysis. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 162-167.	0.6	1
246	Gene Expression Profiling of Renal Cell Carcinoma and Its Implications in Diagnosis, Prognosis, and Therapeutics. Advances in Cancer Research, 2003, 89, 157-181.	1.9	31
247	Inactivation of BHD in sporadic renal tumors. Cancer Research, 2003, 63, 4583-7.	0.4	96
248	Parathyroid tumorigenesis in association with primary hyperparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 51-60.	0.6	1
249	Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. American Journal of Pathology, 2002, 161, 1299-1306.	1.9	36
250	Genetic Screening for MEN1 Mutations in Families Presenting with Familial Primary Hyperparathyroidism. World Journal of Surgery, 2002, 26, 907-913.	0.8	20
251	Genetic and clinical characterization of sporadic cystic parathyroid tumours. Clinical Endocrinology, 2002, 56, 261-269.	1.2	16
252	Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene, 2002, 21, 1117-1122.	2.6	49

#	Article	IF	Citations
253	HRPT2, encoding parafibromin, is mutated in hyperparathyroidismâ€“jaw tumor syndrome. Nature Genetics, 2002, 32, 676-680.	9.4	686
254	Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Research, 2002, 62, 6598-605.	0.4	63
255	C306A single nucleotide polymorphism in the human CEBPD gene that maps at 8p11.1â€“p11.2. Molecular and Cellular Probes, 2001, 15, 395-397.	0.9	2
256	Mapping of the second locus for the Van der Woude syndrome to chromosome 1p34. European Journal of Human Genetics, 2001, 9, 747-752.	1.4	63
257	Birt-Hogg-DubÃ© syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene, 2001, 20, 5239-5242.	2.6	199
258	Molecular Genetics of Familial Hyperparathyroidism. International Journal on Disability and Human Development, 2001, 2, .	0.2	1
259	Malignant melanoma in patients with multiple endocrine neoplasia type 1 and involvement of theMEN1 gene in sporadic melanoma. International Journal of Cancer, 2000, 87, 463-467.	2.3	47
260	Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.. Clinical Endocrinology, 2000, 53, 85-92.	1.2	34
261	Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clinical Endocrinology, 2000, 53, 205-211.	1.2	83
262	The management of familial breast cancer. Breast, 2000, 9, 247-263.	0.9	18
263	Multiple endocrine neoplasia type 1. Seminars in Cancer Biology, 2000, 10, 299-312.	4.3	20
264	Familial Isolated Hyperparathyroidism as a Variant of Multiple Endocrine Neoplasia Type 1 in a Large Danish Pedigree1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 165-167.	1.8	74
265	A Genotypic and Histopathological Study of a Large Dutch Kindred with Hyperparathyroidism-Jaw Tumor Syndrome1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1449-1454.	1.8	96
266	Comparative Genomic Hybridization Reveals Frequent Losses of Chromosomes 1p and 3q in Pheochromocytomas and Abdominal Paragangliomas, Suggesting a Common Genetic Etiology. American Journal of Pathology, 2000, 156, 651-659.	1.9	111
267	Alternative Genetic Pathways in Parathyroid Tumorigenesis*. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3775-3780.	1.8	84
268	Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clinical Endocrinology, 1999, 50, 191-196.	1.2	60
269	THE GENETIC BASIS OF BREAST CANCER AND ITS CLINICAL IMPLICATIONS. Australian and New Zealand Journal of Surgery, 1999, 69, 95-105.	0.2	28
270	Evaluation of Retinoblastoma and Ki-67 Immunostaining as Diagnostic Markers of Benign and Malignant Parathyroid Disease. World Journal of Surgery, 1999, 23, 68-74.	0.8	80

#	Article	IF	Citations
271	Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in theMEN1 gene. , 1999, 26, 35-39.		24
272	Clinical and genetic studies of Van der Woude syndrome in Sweden. Acta Odontologica Scandinavica, 1999, 57, 72-76.	0.9	18
273	Characterization of the mouse Men1 gene and its expression during development. Oncogene, 1998, 17, 2485-2493.	2.6	133
274	Expression and chromosomal localization of the Requiem gene. Mammalian Genome, 1998, 9, 660-665.	1.0	22
275	A Family with Isolated Hyperparathyroidism Segregating a Missense MEN1 Mutation and Showing Loss of the Wild-Type Alleles in the Parathyroid Tumors. American Journal of Human Genetics, 1998, 63, 1544-1549.	2.6	96
276	Thymic Carcinoids in Multiple Endocrine Neoplasia Type 1. Annals of Surgery, 1998, 228, 99-105.	2.1	184
277	A Large Multiple Endocrine Neoplasia Type 1 Family with Clinical Expression Suggestive of Anticipation1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3487-3492.	1.8	59
278	Multiple Endocrine Neoplasia Type 1 and the Search for the Genetic Trigger. Hormone Research, 1997, 47, 179-184.	1.8	3
279	Clinicopathologic Studies of Thymic Carcinoids in Multiple Endocrine Neoplasia Type 1. Medicine (United States), 1997, 76, 21-29.	0.4	119
280	Familial non-VHL non-papillary clear-cell renal cancer. Lancet, The, 1997, 349, 848-849.	6.3	55
281	Construction of a 1.2-Mb Sequence-Ready Contig of Chromosome 11q13 Encompassing the Multiple Endocrine Neoplasia Type 1 (MEN1) Gene. Genomics, 1997, 44, 94-100.	1.3	31
282	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. Journal of Clinical Neuroscience, 1997, 4, 176-180.	0.8	2
283	Breast cancer in six women with neurofibromatosis type 1. Breast, 1997, 6, 155-160.	0.9	5
284	Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Human Genetics, 1997, 99, 342-349.	1.8	72
285	Fine mapping of the MLK-3 gene within 11q13 and its exclusion as the MEN1 susceptibility gene. Human Genetics, 1997, 99, 776-780.	1.8	5
286	Oculopharyngeal muscular dystrophy (OPMD)â€report and genetic studies of an Australian kindred. Clinical Genetics, 1997, 51, 52-55.	1.0	17
287	The phospholipase C Î²3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Human Molecular Genetics, 1994, 3, 1775-1781.	1.4	53
288	Multiple endocrine neoplasia type 1 (MEN1) in two Asian families. Human Genetics, 1994, 94, 468-72.	1.8	13

#	Article	IF	Citations
289	Genetics of Multiple Endocrine Neoplasia Type 1. Annals of the New York Academy of Sciences, 1994, 733, 453-463.	1.8	4
290	Single base mutation in the hormone binding domain of the thyroid hormone receptor Î² gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochemical and Biophysical Research Communications, 1991, 178, 606-612.	1.0	35
291	Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. British Journal of Cancer, 1990, 62, 253-254.	2.9	20
292	Renal-cell carcinomas. , 0, , 579-583.		0